Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1519670 (
tumor angiogenesis
)
6,052
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Seizure-related 6 homolog-like 2 (
SEZ6L2
), which is localized on the cell surface, has been found to be associated with
tumor angiogenesis
and lung cancer progression. However, the role of
SEZ6L2
in hepatocellular carcinoma (HCC) is still unclear. We obtained data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) to investigate
SEZ6L2
expression and regulation in HCC. Then, HCC tissue samples were collected to verify
SEZ6L2
by quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemical staining (IHC). Patient information was collected for survival and prognosis analysis. qRT-PCR, IHC, and bioinformatics analysis showed that the
SEZ6L2 protein
was highly expressed in HCC samples. Clinical data showed that high
SEZ6L2 protein
expression was correlated with tumor-node-metastasis (TNM) stages (
P
= 0.046), tumor number (
P
= 0.016), and tumor size (
P
= 0.029). Meanwhile, SEZ6L2 overexpression was closely associated with poor overall survival and disease-free survival in HCC patients. Moreover,
SEZ6L2
is an independent prognostic predictor for the survival of HCC patients. This study suggests a significant correlation between
SEZ6L2
and HCC, which means that
SEZ6L2
may potentially serve as a useful prognostic biomarker for HCC patients.
...
PMID:Upregulated Seizure-Related 6 Homolog-Like 2 Is a Prognostic Predictor of Hepatocellular Carcinoma. 3214 67